Capricor Therapeutics Crashes 64% to $7 Amid Clinical Irregularity Class Action

The Quick Take

• Capricor Therapeutics shares fell 64% to $7 after irregularities emerged in the clinical development of lead drug Deramiocel.
• A class action lawsuit has been filed with shareholders given until September 28, 2026 to join the legal action.
• The collapse reflects complete loss of investor confidence in the company's primary therapeutic asset pipeline.

Capricor Therapeutics experienced a devastating 64% single-session decline to $7 per share after information surfaced regarding irregularities in the clinical development of Deramiocel, its lead therapeutic candidate. German financial platform Aktiencheck highlighted the class action lawsuit opened for investors, with a participation deadline of September 28, 2026. Such collapses in biotech names typically follow revelation of data manipulation, trial design irregularities, or key opinion leader disavowal of clinical data, all of which render the regulatory pathway to approval extremely uncertain.

The magnitude of the decline — 64% — suggests complete repricing of the probability of Deramiocel achieving FDA approval, effectively marking the asset as having near-zero near-term commercial value. Class action filings of this nature typically drag on management attention and legal costs for 12-18 months, further impairing the company's ability to raise capital or pursue alternative programs. Peer biotechs in the rare disease muscular dystrophy space — where Deramiocel was targeting Duchenne muscular dystrophy — face sympathy pressure as investors reassess clinical risk in the category.

The critical event is the content of the securities class action complaint, which will detail the specific nature of the clinical irregularities and their impact on the FDA review process. Any FDA communication — whether a complete response letter or clinical hold — represents the next hard catalyst. The macro variable is capital availability for small-cap biotech: in a tight-rate environment, biotechs with compromised lead assets struggle to refinance and often face forced dilution or outright acquisition at distressed valuations.

Synthesized from 1 source.